Skip to main content
SpringerLink
Log in

Asiatische Heilpilze

Asian medical mushrooms

  • In der Diskussion: Komplementäre Onkologie
  • Published:
Der Onkologe Aims and scope

Zusammenfassung

Asiatische Heilpilze enthalten komplexe Kohlenhydratverbindungen, die immunmodulierende Eigenschaften besitzen. Experimentelle Daten sprechen sowohl für direkte als auch indirekte Wirkungen auf Tumorzellen. Viel versprechende präklinische Daten belegen eine antitumorale Wirkung bei verschiedenen Tumorarten. In klinischen Studien wurden die alleinige Wirkung der Pilze und die Kombination mit Zytostatika geprüft. Die bisher vorliegenden Studiendaten sind unter wissenschaftlichen Gesichtspunkten nicht ausreichend, um einen therapeutischen Einsatz außerhalb von Studien zu befürworten. Patienten sollten über mögliche Nebenwirkungen und Kontaminationen von Präparaten informiert werden.

Abstract

Medical mushrooms from Asia contain complex polysaccharides with immunomodulating properties. Experimental data give evidence for both direct and indirect action on targets of tumor cells, and preclinical data show promising effects on different tumor types. In clinical studies, the effect of medical mushrooms was tested, both as the single agent and in combination with chemotherapy. From a scientific point of view, published data are not yet conclusive, and medical mushrooms should not be used outside of studies. Patients should know putative side effects and should be informed about putative contamination of the products.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Ehlers S (2003) Chinesische Heilpilze. Haug, Stuttgart

  2. Lelley J (1997) Die Heilkraft der Pilze – Gesund durch Mykotherapie. Econ Taschenbuch, München

  3. Ehlers S (2005) Mykotherapie - Heilbehandlung mit Pilzen. In Ratgeber unkonventionelle Krebstherapien. Edited by Münstedt K. ecomed Medizin, Lansberg/Lech 301–306

  4. Wasser SP (2002) Medicinal mushrooms as a source of antitumor and immunomodulating polysaccharides. Appl Microbiol Biotechnol 60:258–274

    Article  PubMed  CAS  Google Scholar 

  5. Ooi VE, Liu F (2000) Immunomodulation and anti-cancer activity of polysaccharide-protein complexes. Curr Med Chem 7:715–729

    PubMed  CAS  Google Scholar 

  6. Akramiene D, Kondrotas A, Didziapetriene J, Kevelaitis E (2007) Effects of beta-glucans on the immune system. Medicina (Kaunas) 43:597–606

    Google Scholar 

  7. Borchers AT, Stern JS, Hackman RM et al (1999) Mushrooms, tumors, and immunity. Proc Soc Exp Biol Med 221:281–293

    Article  PubMed  CAS  Google Scholar 

  8. Chen J, Seviour R (2007) Medicinal importance of fungal beta-(1→3), (1→6)-glucans. Mycol Res 111:635–652

    Article  PubMed  CAS  Google Scholar 

  9. Büssing A (2008) Pharmakologische Hinweise zur Anwendung von Ganoderma lucidum bei Tumorerkrankungen. Dtsch Zeitschrift Onkol 40:62–65

    Article  Google Scholar 

  10. Boh B, Berovic M, Zhang J, Zhi-Bin L (2007) Ganoderma lucidum and its pharmaceutically active compounds. Biotechnol Annu Rev 13:265–301

    Article  PubMed  CAS  Google Scholar 

  11. Sliva D (2003) Ganoderma lucidum (Reishi) in cancer treatment. Integr Cancer Ther 2:358–364

    Article  PubMed  Google Scholar 

  12. Lin ZB, Zhang HN (2004) Anti-tumor and immunoregulatory activities of Ganoderma lucidum and its possible mechanisms. Acta Pharmacol Sin 25:1387–1395

    PubMed  CAS  Google Scholar 

  13. Jiang J, Slivova V, Sliva D (2006) Ganoderma lucidum inhibits proliferation of human breast cancer cells by down-regulation of estrogen receptor and NF-kappaB signaling. Int J Oncol 29:695–703

    PubMed  CAS  Google Scholar 

  14. Zaidman BZ, Wasser SP, Nevo E, Mahajna J (2007) Androgen receptor-dependent and -independent mechanisms mediate Ganoderma lucidum activities in LNCaP prostate cancer cells. Int J Oncol 31:959–967

    PubMed  CAS  Google Scholar 

  15. Zaidman BZ, Wasser SP, Nevo E, Mahajna J (2008) Coprinus comatus and Ganoderma lucidum interfere with androgen receptor function in LNCaP prostate cancer cells. Mol Biol Rep 35:107–117

    Article  PubMed  CAS  Google Scholar 

  16. Liu J, Shimizu K, Konishi F et al (2007) The anti-androgen effect of ganoderol B isolated from the fruiting body of Ganoderma lucidum. Bioorg Med Chem 15:4966–4972

    Article  PubMed  CAS  Google Scholar 

  17. Stanley G, Harvey K, Slivova V et al (2005) Ganoderma lucidum suppresses angiogenesis through the inhibition of secretion of VEGF and TGF-beta1 from prostate cancer cells. Biochem Biophys Res Commun 330:46–52

    Article  PubMed  CAS  Google Scholar 

  18. Nonaka Y, Shibata H, Nakai M et al (2006) Anti-tumor activities of the antlered form of Ganoderma lucidum in allogeneic and syngeneic tumor-bearing mice. Biosci Biotechnol Biochem 70:2028–2034

    Article  PubMed  CAS  Google Scholar 

  19. Yao PY, Gao ZM, Fang ST, Ke L (n d) Evaluation of the subsidiaryeffects of taking PSP orally on the chemotherapy of stomach cancer. Shanghai 269–270

  20. Yang QY, Wang MM (n d) The effect of ganoderma lucidum extract against fatigue and endurance in the absence of oxygen. Taipe 101–113

  21. Chen X, Hu ZP, Yang XX et al (2006) Monitoring of immune responses to a herbal immuno-modulator in patients with advanced colorectal cancer. Int Immunopharmacol 6:499–508

    Article  PubMed  CAS  Google Scholar 

  22. Gao Y, Tang W, Dai X et al (2005) Effects of water-soluble Ganoderma lucidum polysaccharides on the immune functions of patients with advanced lung cancer. J Med Food 8:159–168

    Article  PubMed  CAS  Google Scholar 

  23. Gao Y, Zhou S, Jiang W et al (2003) Effects of ganopoly (a Ganoderma lucidum polysaccharide extract) on the immune functions in advanced-stage cancer patients. Immunol Invest 32:201–215

    Article  PubMed  Google Scholar 

  24. Kwok Y, Ng KF, Li CC et al (2005) A prospective, randomized, double-blind, placebo-controlled study of the platelet and global hemostatic effects of Ganoderma lucidum (Ling-Zhi) in healthy volunteers. Anesth Analg 101:423–426, table

    Article  PubMed  CAS  Google Scholar 

  25. Wachtel-Galor S, Tomlinson B, Benzie IF (2004) Ganoderma lucidum („Lingzhi“), a Chinese medicinal mushroom: Biomarker responses in a controlled human supplementation study. Br J Nutr 91:263–269

    Article  PubMed  CAS  Google Scholar 

  26. Yuen JW, Gohel MD (2005) Anticancer effects of Ganoderma lucidum: A review of scientific evidence. Nutr Cancer 53:11–17

    Article  PubMed  CAS  Google Scholar 

  27. Nakano H, Namatame K, Nemoto H et al (1999) A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: Effect on prolongation of survival and improvement of quality of life. Kanagawa Lentinan Research Group. Hepatogastroenterology 46:2662–2668

    PubMed  CAS  Google Scholar 

  28. Taguchi T (1987) Clinical efficacy of lentinan on patients with stomach cancer: End point results of a four-year follow-up survey. Cancer Detect Prev Suppl 1:333–349

    PubMed  CAS  Google Scholar 

  29. Tari K, Satake I, Nakagomi K et al (1994) Effect of lentinan for advanced prostate carcinoma. Hinyokika Kiyo 40:119–123

    PubMed  CAS  Google Scholar 

  30. Wakui A, Kasai M, Konno K et al (1986) Randomized study of lentinan on patients with advanced gastric and colorectal cancer. Tohoku Lentinan Study Group. Gan To Kagaku Ryoho 13:1050–1059

    PubMed  CAS  Google Scholar 

  31. Taguchi T, Furue H, Kimura T et al (1985) Results of phase III study of lentinan. Gan To Kagaku Ryoho 12:366–378

    PubMed  CAS  Google Scholar 

  32. Fisher M, Yang LX (2002) Anticancer effects and mechanisms of polysaccharide-K (PSK): Implications of cancer immunotherapy. Anticancer Res 22:1737–1754

    PubMed  CAS  Google Scholar 

  33. Ng TB (1998) A review of research on the protein-bound polysaccharide (polysaccharopeptide, PSP) from the mushroom Coriolus versicolor (Basidiomycetes: Polyporaceae). Gen Pharmacol 30:1–4

    PubMed  CAS  Google Scholar 

  34. Niimoto M, Hattori T, Tamada R et al (1988) Postoperative adjuvant immunochemotherapy with mitomycin C, futraful and PSK for gastric cancer. An analysis of data on 579 patients followed for five years. Jpn J Surg 18:681–686

    Article  PubMed  CAS  Google Scholar 

  35. Nakazato H, Koike A, Ichihashi H et al (1989) An effect of adjuvant immunochemotherapy using krestin and 5-FU on gastric cancer patients with radical surgery (first report)--a randomized controlled trial by the cooperative study group. Study Group of Immuno-chemotherapy with PSK for Gastric Cancer. Gan To Kagaku Ryoho 16:2563–2576

    PubMed  CAS  Google Scholar 

  36. Mitomi T, Kyoji O (1986) Clinical study of PSK as an adjuvant immunochemotherapeutic agent against gastric cancer. Gan To Kagaku Ryoho 13:2532–2537

    PubMed  CAS  Google Scholar 

  37. Nakajima T, Inokuchi K, Hattori T et al (1989) Multi-institutional cooperative study of adjuvant immunochemotherapy in gastric cancer--five-year survival rate. Gan To Kagaku Ryoho 16:799–806

    PubMed  CAS  Google Scholar 

  38. Sakamoto J, Nakazato H (1993) Evaluation of adjuvant immunochemotherapy in advanced gastric cancer. Gan To Kagaku Ryoho 20:2525–2530

    PubMed  CAS  Google Scholar 

  39. Ito I, Mukai M, Ninomiya H et al (2008) Comparison between intravenous and oral postoperative adjuvant immunochemotherapy in patients with stage II colorectal cancer. Oncol Rep 20:1189–1194

    PubMed  CAS  Google Scholar 

  40. Ito I, Mukai M, Ninomiya H et al (2008) Comparison between intravenous and oral postoperative adjuvant immunochemotherapy in patients with stage III colorectal cancer. Oncol Rep 20:1521–1526

    PubMed  CAS  Google Scholar 

  41. Sakai T, Yamashita Y, Maekawa T et al (2008) Immunochemotherapy with PSK and fluoropyrimidines improves long-term prognosis for curatively resected colorectal cancer. Cancer Biother Radiopharm 23:461–467

    Article  PubMed  CAS  Google Scholar 

  42. Ishibashi K, Ishiguro T, Kuwabara K et al (2008) Administration of polysaccharide K (PSK) for stage III colorectal cancer in clinical practice. Gan To Kagaku Ryoho 35:2283–2285

    PubMed  CAS  Google Scholar 

  43. Sakamoto J, Morita S, Oba K et al (2006) Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curatively resected colorectal cancer: a meta-analysis of centrally randomized controlled clinical trials. Cancer Immunol Immunother 55:404–411

    Article  PubMed  CAS  Google Scholar 

  44. Nishiwaki Y, Furuse K, Fukuoka M et al (1990) A randomized controlled study of PSK combined immuno-chemotherapy for adenocarcinoma of the lung. The Advanced Lung Cancer Immuno-chemotherapy Study Group. Gan To Kagaku Ryoho 17:131–136

    PubMed  CAS  Google Scholar 

  45. Cassileth BR, Lucarelli CD (2003) Herb-Drug Interactions in Oncology. B.C. Decker Inc, London

  46. Ernst E, Pittler MH, Wider B (2006) The desktop guide to complementary and alternative medicine. An evidence-based approach. Mosby Elsevier

  47. Nakatsugawa M, Takahashi H, Takezawa C et al (2003) Hericium erinaceum (yamabushitake) extract-induced acute respiratory distress syndrome monitored by serum surfactant proteins. Intern Med 42:1219–1222

    Article  PubMed  Google Scholar 

  48. Nakamura T (1992) Shiitake (Lentinus edodes) dermatitis. Contact Dermatitis 27:65–70

    Article  PubMed  CAS  Google Scholar 

  49. Hanada K, Hashimoto I (1998) Flagellate mushroom (Shiitake) dermatitis and photosensitivity. Dermatology 197:255–257

    Article  PubMed  CAS  Google Scholar 

  50. Levy AM, Kita H, Phillips SF et al (1998) Eosinophilia and gastrointestinal symptoms after ingestion of shiitake mushrooms. J Allergy Clin Immunol 101:613–620

    Article  PubMed  CAS  Google Scholar 

  51. Kai N, Ishii H, Iwata A et al (2008) Chronic hypersensitivity pneumonitis induced by Shiitake mushroom cultivation: Case report and review of literature. Nihon Kokyuki Gakkai Zasshi 46:411–415

    PubMed  Google Scholar 

  52. Bundesinstitut für Risikobewertung (BfR) (2004) Gesundheitliches Risiko von Shiitake-Pilzen. Stellungnahme des BfR vom 23. Juni 2004Stellungnahme des BfR vom 1–7 2004

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Medizintheorie und Komplementärmedizin, Universität Witten/Herdecke, Gerhard-Kienle-Weg 4, 58313, Herdecke, Deutschland

    A. Büssing

  2. Onkologische Abteilung, Habichtswald-Klinik Kassel, Kassel, Deutschland

    J. Hübner

Authors
  1. A. Büssing
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Hübner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Büssing.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Büssing, A., Hübner, J. Asiatische Heilpilze. Onkologe 15, 519–525 (2009). https://doi.org/10.1007/s00761-009-1594-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00761-009-1594-3

Schlüsselwörter

keywords

Search

Navigation